The anticonvulsant activity (ED50) of three synthetic eugenol derivatives – phenyleugenol (PE), benzyleugenol (BE), phenylethyleugenol (PEE) – was compared to that of common antiepileptics – diphenyl-hydantoine (DPH), phenobarbital (PB), diazepam (DZ) -and the naturally occurring methyleugenol (ME) in the maximal electroshock seizure (MES) test and the subcutaneous pentylenetetrazol-induced minimal seizure (s.c. PTZ) test. Neurotoxicity (ND50) and lethality (LD50) were determined in order to evaluate the protective index (PI = ND50/ED50) and the therapeutic index (TI = LD50/ED50). BE, PE and PEE are shown to be effective anticonvulsants by the MES test in mice with PIs equal to or higher than that of PB and DZ. Furthermore, BE and PEE were significantly more potent in rats than in mice. Experiments on the duration of protection revealed an immediate onset, a steady decline within the following 4 h and reappearance of activity 6–8 h after injection of PE, BE, and PEE but not ME. In the s.c. PTZ test in mice, the eugenol derivatives were active in increasing the latency to the first minimal seizure but less active in its prevention. As to the TIs, PEE showed a smaller margin of safety by the two tests than BE and PE. The latter compounds have high LD50s and consequently high TIs.

Keywords:
Eugenol, Benzyleugenol, Antiepileptics, Convulsion, Electroshock seizures, Therapeutic index
This content is only available via PDF.
© 1983 S. Karger AG, Basel
1983
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.